The U.S. Food and Drug Administration (FDA) has approved four anti-PD-1 antibodies (nivolumab, pembrolizumab, cemiplimab, and dostarlimab) and three anti-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) for the treatment of nearly all types of cancers [1,2,3,4]. The gene discussed is CD274; the disease is cancer.